Seres Therapeutics, Inc. (MCRB) Net margin 2016–2025
Seres Therapeutics, Inc. (MCRB) net profit margin by fiscal year — reported net income divided by reported revenue.
721.9%FY2025 · since FY2016: -420.7% → 721.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 721.9% | — |
| FY2022 | -3509.5% | -3463.9 pp |
| FY2021 | -45.6% | +703.6 pp |
| FY2020 | -749.2% | -490.7 pp |
| FY2019 | -258.5% | +109.1 pp |
| FY2018 | -367.6% | -89.1 pp |
| FY2017 | -278.4% | +142.3 pp |
| FY2016 | -420.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice